Company

About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.

History

2021

  • Aug. 1st rank for outpatient prescriptions in the first half for 4 consecutive years
  • Jul. Hanmi-Lego ChemBio jointly develop dual antibody ADC anticancer drug
  • NIH visits Hanmi Fine Chemicals on-site verification of mRNA competency
  • Jun. Founder of Hanmi, 'Lim Seong-ki Foundation' launched
  • Joint research on innovative new drug targeting lung cancer with Dankook University
  • May. President Woo, received the Gold Tower medal of Industrial Merit on the Day of Invention
  • Hanmi-Genexin, Covid 19 Vaccine Production Contract
  • US FDA additionally designates LAPSTriple Agonist as an orphan drug
  • Apr. AmosartanQ enters Russian Market
  • US FDA designates LAPSGLP-2 Analog as a Fast Track
  • Hanmi received a commendation from the Fair Trade Commissioner
  • Mar. Opened Daycare Center for children of employees
  • New biologic drug Rolontis, first approval in Korea
  • US FDA designates Poziotinib as a Fast Track
  • Rosuzet enters Mexico Market
  • Feb. NASH Innovative Drug, awarded Korea New Drug Development Technology
  • Rosuzet achieved No. 1 in sales of prescription drugs in korea
  • Launched the world's first 4 drug complex 'Amosartan XQ'
  • Jan. 1st rank for outpatient prescriptions for 3 consecutive years
  • FDA approves Phase 2 clinical trial for two innovative drugs of Hanmi
  • Launched the world's first Esomeprazole double delayed release 'Esomezoldial'

2020

  • Dec. Spectrum FDA pre-meeting succeded, expected BLA application of'Poziotinib'
  • Hanmi presented the results of AML treatment clincial trials HM43239 atASH
  • Athenex presented results of Oraxol Phase 3 clinical trials
  • Nov. Hanmi-GC, aggreementon developing innovative new drugs in 'rare diseases'
  • MFDS approved ,'Amosartan XQ', world first 4-combination durg
  • Oct. Hanmi awarded National Assembly Women and Family Chairperson Award
  • JVM automatic dispensing machine 'NSP' launched in Norway
  • Sep. Hanmi and MSD cooperation agreement on clinical trials and supply
  • US FDA designates “Oraxol” for priority review
  • Aug. Hanmi presented the results of LAPS Triple Agonist clinical trial at EASL
  • Inauguration of Hanmi Pharmaceutical Group Chairman Song Young-sook
  • Hanmi and MSD License Agreement of LAPS GLP/Glucagon(Efinopegdutide) todevelop NASH Treatment
  • Chairman Lim Seong-ki, founder of Hanmi Pharmaceutical Group, passed away
  • Jul. Announced 2020 2Q earnings 243.4 billion won in sales, 19.8% R&Dinvestment against sales
  • Spectrum presents clinical trial results of Poziotinib Phase 2
  • LAPS Triple Agonist receives designation for US FDA Fast Track
  • Jun. LAPSGlucagon Analog receives FDA RPD designation
  • LAPSGLP-2 Analog receives FDA RPD designation
  • Spectrum presents clinical trial results of Rolontis at AACR
  • Gugu' released In Japna as a BPH treatment
  • Announced 6 new clinical trial results at ADA
  • Released low-dose Amodipine(2.5mg)
  • Spectrum presents Phase 2 clinical trial results of Oraxol
  • May. Hanmihealthcare donated 156,000 'Wanjun' soymilk
  • Applies Rolontis BLA to the KFDA
  • Apr. Launched 'LIVE Symposium 2020'
  • Announced 2020 1Q earnings 288.2 billion won in sales, 19% R&D investment against sales
  • Hanmi Pharmaceutical set up an audit committee
  • Mar. LAPSTriple Agonist receives FDA RPD desination for PSC and PBC
  • Feb. Announced 2019 earnings 1.16 trillion won in sales, 18.8% R&D investment against sales
  • JVM Packaging System, Launched in Canadian Walmart
  • Announced 2019 earnings 110.1 billion won, increased 6.3 percent on-year
  • Hanmi announces the largest number of blockbuster products in 2019.
  • Signed a partnership with GC to develop Rare Disease new drugs
  • Jan. Announced achieving 'Top 1' market share of hypertension medication in Korea
  • A Joint agreement with STANDIME on the Development for new drugs based on AI
  • Hanmi unveiled new R&D strategy at 38th JP Morgan Healthcare Conference
  • Certified International Standard for business countinuity Management System (ISO22301)

2019

  • Dec. Maintained CP-rated 'AA' for 6 years by the Fair Trade Commission
  • 39th blood donation, a total of 8,218 participanted
  • Hanmi women's Association Hold 11th Charity flea market
  • Hanmi Wins Prime Minister's Award for 'Korea's Loved Companies'
  • Announced 2 new blood cancer drug at ASH
  • Patent court ruled nullifying drug-food pirates registration of 'palpal'
  • Hanmi Announced collaboration to develop FLX475 with RAPT
  • The 18th Hanmi Cham Prize for the Yonsei Missionary center and the Muryang
  • Nov. PENTAMBODY Phase 1 clinical trial started
  • Hanmi Science, North Gyeongsang Province-POSTECH-Pohand signed MOU
  • Patent court ruled nullifying Health-function food pirates registration of 'palpal'
  • Oct. Announced 2019 3Q earnings 265.7 billion won in sales, 20% R&D investment against sales
  • Spectrum, reapply Rolontis BLA to the FDA
  • The Korean doctor Association awarded Hanmi with a merit prize
  • Spectrum listed a clinical result of Poziotinib Posotinip study in the Kenssel medical journal
  • JVM, extension of pouch-roll production plant
  • Certified best institution for Human Resource Development (HRD) from government
  • Sep. Atenex, Releases clinical result of Oraxol in ESMO
  • Hanmi presents clinical trial results of Four clinical outcomes at EASD
  • Amosartan, 11th clinical outcomes listed in the SCI-class international journal
  • Signed a partnership with Phanes to develop dual and multiple antibodies
  • Amosartan Plus-Q, first entered in Latin America market
  • GMP inspectors from 10 Southeast Asian countries visited Paltan Smart Plant
  • Spectrum, disclosed Poziotinib
  • Hanmi selected as an Innovative pharmaceutical companies ranked No. 1 in Korea and No. 12 in Asia
  • Aug. Atenex Announce key clinical results of phase 3 clinial trial
  • Jul. Announced 2019 2Q earnings 270.4 billion won in sales, 17% R&D investment against sales
  • Spectrum added poziotinib cohort three study
  • Jun. CEO kwon Se Chang awared 'KASBP Appreciation Award’ at KASBP spring symposium
  • Confirms global competitiveness innovative drugs for NASH, rare diseases and targeted anti-cancer
  • Spectrum and Atenex Announce results of new drugs
  • Spectrum presents clinical trial results of Belvarafenib at AACR
  • May. Phase 3 results of “Rovelito” were published in the international journal
  • Spectrum "'poziotinib’ global phase 2 cohort two study patient collection completed"
  • Hanmi receives FDA orphan drug designation fin treatment of short bowel syndrome
  • Apr. JVM Packaging System, Launched in the Russian market
  • Genetech presents 4 results of clinical trial at AACR
  • Mar. Co promotion agreement of ‘Diquas’ with Santen
  • Received Seoul Metropolitan Government's Best Practices for Public Taxpayers
  • Rovelito Released clinical results of Phase 4 in the international journal
  • Feb. Hanmi Pharmaceutical-MPO, 7th concert was succesfully ended
  • Hanmi Pharmaceutical set up an audit committee
  • Jan. Announced 2018 earnings 1.16 trillion won in sales, 19% R&D investment against sales
  • Certified International Standard for Information Protection Management System (ISO27001)
  • Hanmi unveiled new R&D strategy at JP Morgan Healthcare Conference
  • Oraxol Global 3-phase patient collection completed
  • Spectrum "'poziotinib’ global phase 2 cohort one study patient collection completed"

2015

  • Dec.JVM launches new pharmaceutical packaging machine that can speed up the automatic dispensing procedure and save wrapping paper
  • LAPSCOVERY applied new bio drug Rolontis submitted for US FDA approval
  • Nov.Europe’s No.1 Pharmacy chain adopts JVM ‘s automatic pharmaceutical packaging machine
  • Hanmi conducts full-scale anti-smoking campaign at all its workplaces
  • Oct.Hanmi presents clinical trial results of the treatments applied with LAPSCOVERY technology at EASD
  • Athenex gets FDA nod for testing oral breast cancer treatment, Eribulin
  • Hanmi receives FDA orphan drug designation for HM43239 in treatment of AML
  • Sep.Spectrum unveils the latest interim results of the phase 2 clinical trial on ‘poziotinib’ at WCLC
  • Aug.Monterizine Capsule phase 3 clinical test results featured in the Journal of Clinical Therapeutics
  • July.Releases phase 3 clinical result of Rolontis in an oral presentation at the MASCC
  • Slated to market and sell Hugel’s Gugu-fill(Hyaluronic Acid Filler)
  • Jun.Presents three next-generation anti-cancer drugs at ASCO
  • Releases clinical results of Amosartan/Rovelito at ESH
  • Launches Monterizine Chewable Tab for children
  • May.Wins FDA nod for arthritis treatment ‘Hyalrheuma’
  • Sanofi begins phase 3 trials of Hanmi’s diabetes drug candidate ‘efpeglenatide’
  • Apr. Janssen starts phase 2 study on HM12525A, a biologic drug for the treatment of diabetes and obesity developed by Hanmi
  • Unveils three new anti-cancer drug candidates at AACR
  • Spectrum presents clinical trial results of poziotinib at AACR
  • Wins FDA approval of LAPSTriple Agonist phase 1 clinical trial
  • Oraxol gets orphan drug designation for angiosarcoma
  • JVM, an affliliate of Hanmi awarded for excellence in corporate disclosure
  • Spectrum publishes the trial results for poziotinib, a non-small-cell lung cancer treatment on Nature Medicine
  • Mar. Hanmi Tams 0.4mg phase 3 clinical test results featured in the Journal of Clinical Therapeutics
  • Selected the short track speed skating gold medalist Kim Alang as its new model for Tenten, a chewable nutritional supplement
  • Feb.LAPSGlucagon Analog receives FDA Breakthrough Therapy Designation in congenital hyperinsulinemia
  • Spectrum presents ‘Rolontis’ met the Primary Endpoint in the Phase 3 ADVANCE study… sets to file BLA within 4Q
  • Sanofi sets to start two phase 3 clinical trials of efpeglenatide in 2018
  • Received industry first ‘BPW Gold Award’ for promoting gender equality
  • Jan.Promotes innovative drugs for NASH, rare diseases and targeted anti-cancer at JP Morgan event
  • Reports 916.6 billion won in revenue in 2017, operating profit soars 212.3%

2015

  • DecHosts employee-driven charity events to make kimchi to support underprivileged
  • NovAdopts industry-first ISO 37001 to prevent illegal rebates and organizational corruption
  • Sanofi starts phase 3 clinical trials on Hanmi’s diabetes treatment ‘efeglenatide’
  • ‘Amosartan Q’ phase 3 clinical test results featured in the Journal of Clinical Therapeutics
  • JVM receives 2017 Korea Technology Awards for its automated drug management system ‘INTIpharm’
  • OctPhase 3 results of ‘Amosartan Plus’ were published in the Journal of Clinical Therapeutics
  • Spectrum highlights poziotinib in at WCLC
  • Releases hypertension-hyperlidipemia three-compound complex Amosartan Q(amlodipine +losartan+rosuvastatin)
  • SepPresents the clinical trial results of NASH, rare diseases and targeted anti-cancer drug at EASD
  • Released 3-compound hypertension drug ‘Amosartan Plus (losartan/amlodipine/chlortalidon)’
  • AugPhase 3 results of ‘Gugutams’ were published in the Journal of Sexual Medicine
  • JulyHanmi launched the first osteoporosis therapy in the world which combines SERM with Vitamin D
  • Hanmi received approval of Amosartan Q, a hypertension-hyperlipidemia three-compound complex
  • Hanmi’s Esomezol listed in U.S. drug encyclopedia
  • Hanmi launched ‘Monterizine’, a combination drug for patients with both asthma and allergic rhinitis
  • JunHanmi presented its 2 candidate substance of biologic applied with ‘LAPSCOVERY’ at ADA
  • Hanmi presented the clinical trial results of hypertension three-compound complex at EHS
  • Hanmi won approval for Amosartan Plus, a 3 in 1 combination drug for hypertension
  • April ‘RaboneD’, a first combination drug of Raloxifene HCI and Cholecalciferol approved for sale in Korea
  • Hanmi launched ‘Besigum’, a treatment for overactive bladder syndrome treatment
  • May Hanmi received approval of a 1st-phase clinical test of the combination therapy of RAF target anti-cancer drug HM95573
  • 'Monterizine', a first combination drug for asthma-rhinitis approved for sale in Korea
  • Phase III trial results of 'Gugutams' presented at 2017 AUA
  • Jan Hanmi-MSD, signed an agreement to export “Rosuzet” to export to 23 countries
  • Hanmi unveiled new R&D strategy at JP Morgan Healthcare Conference

2015

  • DecPreclinical trial results of “HM95573 (pan-RAF inhibitor)” were presented at Europe Cancer Symposium
  • Hanmi and Ajou University entered into a new anticancer drug development partnership for the development of a novel stem cell therapy
  • Hanmi launched Korea’s first urological combination drug for prostatic hypertrophy and erectile dysfunction “Gugutams”
  • NovPhase 3 results of “Rovelito” were published in the international science journal
  • SepPhase 3 clinical trial results of tamsulosin-tadalafil combined treatment “Gugutams” won the best subject award at the International Society for Sexual Medicine (ISSM)
  • Hanmi signed an exclusive license agreement with Genentech for a Novel Oral RAF inhibitor
  • AugPhase 3 results of “Rosuzet” were published in the international science journal
  • JulHanmi Pharmaceutical Group to establish venture capital firm ‘Hanmi Ventures’
  • Hanmi presented the research results of long acting diabetes-obesity medicines at 2016 ADA
  • Hanmi Science acquires medication management automation company JVM
  • JunHanmi presented the clinical trial results of two targeted anti-ancer drugs at 2016 ASCO
  • AprHanmi wins presidential citation for playing model role in promoting compliance program
  • Hanmi Science purchases land in Yantai Economic & Technological Development Zone in China
  • MarSpectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
  • Hanmi launches Prostatic Hyperplasia medication ‘Hanmi Tams 0.4mg’
  • Hanmi launches antiviral medication ‘Hanmi Flu’
  • FebHanmis’sales reach record high of KRW 1.3175 trillion
  • Hanmi attends JP Morgan Healthcare Conference, presenting new R&D projects
  • JanHanmi founder and chairman, Lim Sung-ki to give away shares worth KRW 110 bil. to employees

2015

  • Dec Hanmi launches oral wound rinse ‘MuGard’ for cancer patients
  • 3rd-generation EGFR TKI, HM61713(Olmutinib), receives FDA Breakthrough Therapy Designation in lung cancer
  • Spectrum Announces Agreement with FDA on the Special Protocol Assessment(SPA) for the Registrational Trial of eflapegrastim, a Novel, Long Acting G-CSF in Patients with Breast Cancer
  • Nov Hanmi and Sanofi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments
  • Hanmi and ZAI Lab execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China
  • Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug(IND) Application for Poziotinib
  • Hanmi launches new dual-action hyperlipidemia drug 'Rosuzet'
  • Hanmi Signs an Exclusive License Agreement with Janssen Pharmaceuticals, Inc. to Develop a Novel Biologic for Treatment of Diabetes and Obesity
  • OctHanmi set new record in sales in Q3
  • Hanmi Enters Agreement with Serenus Bio to Bring Combination Therapy to Fight off Hypertension in Africa
  • SepHanmi presented the results of Efeglenatide's Phase IIb clinical trial at 2015 EASD
  • AugHanmi Enters Research Collaboration for a Next Generation Biologic Drug with a Bio-Venture
  • JunHanmi to Present 3rd-generation EGFR TKI, HM61713 at 2015 ASCO
  • Hanmi to Present its New Diabetes Drugs Including Quantum Project at 2015 ADA Scientific Sessions
  • AprHanmi to Build “Global Smart Facility” for Export of Finished Products
  • MarLicensed out ‘Poziotinib’ (targeted anticancer agent) to Spectrum Pharma in US
  • Beginning US Phase Ⅲ clinical trial for its osteoarthritis medicine Hyalrheuma
  • Licensed out immunological therapy ‘HM71224’ to Eli lilly (Deal size : 780 bil won)
  • Started phase 2 clinical trial of new antibody target lung cancer drug, HM61713
  • Presented a new long-acting human growth hormone drug (LAPSrhGH) at the endocrine society conference
  • FebInitiated phase I clinical trial of first in class weekly insulin in US
  • Targeted anti-cancer agents Poziotinib, goes on phase 2 to expand indications for Breast cancer
  • JanCP Grade impoved from BBB to A
  • Participated in JP Morgan healthcare conference
  • $20 million strategic investment with Allegro Ophthalmics(ophthalmic Bioventure)
  • Initiated phase I clinical trial of first in class weekly insulin in US
  • 35th Blood Drive...a total of 4,883 people participated
  • Co promotion agreement of ‘Godex’ with Celltrion

2014

  • NovHanmi new RFID reader, grand prize for national excellence patent award
  • Phase 1 clinical trial of HM95573,a next-generation targeted therapy for melanoma treatment
  • OctBeijing Hanmi, received 'Presidential Prize' at 2014 Korea well-respected corporate awards
  • Received 'Minister Prize of Health and Welfare' at Sharing Korea awards
  • SepDiabetes-obesity biologics, presented at EASD
  • AugLicense agreement with Luye pharma group for targeted anti-cancer dug 'Poziotinib' in China
  • Diabetes biologic, 'LAPS efpeglenatide', completed patient recruitment in phase IIb clinical trial
  • JulContract with Actavis for exporting a hyaluronic acid injection
  • Hanmi opened the official blog 'Saranghanmida'
  • Hanmi-Novartis, diabetes treatment 'Galvus' co-promotion
  • JunTriaxone, obtained market authorization in 4 EU countries
  • sup>LAPSInsulin, weekly diabetes drug, presented at ADA
  • Rheumatoid arthritis drug, HM71224, presented at EULAR
  • The 8th Hanmi mid-small hospital award, Seungwon Hong, Director of Daejeon Christian General Hosipital
  • Plant in Pyeongtaek awarded for joining PIC/S by Korea Food & Drug Administration
  • May Diabetes-obesity new drug (LAPS-GLP-1/GCG) enters into global phase 1
  • Apr Probiotics for kids in Beijing Hanmi, 'Mamiai' is registered as China Famous Trade Mark
  • Decided to build an extension of BioPlant in Pyeongtaek
  • Received 'fair trade corporation' award by Fair Trade Commission
  • Launched Fluterol, DPI type asthma treatment drug
  • Mar 4th shareholders meeting of Hanmi Pharmaceuticals / 41st shareholders meeting of Hanmi Science
  • License agreement with Access Pharmaceuticals for Korean commercialization of 'Mugard'
  • Feb Hanmi-MSD, mutual co-promotion agreement for the sales of 12 products
  • Succeeded in seasoned equity offering (1 million shares)
  • Jan Hit 100 billion won in research and development as the first listed pharmaceutical company
  • Only one in the pharmaceutical industry to receive CP certificate(BBB grade)

2014

  • DecHIMD for the treatment of gastroesophageal reflux disease, Esomezol, launched in the United States
  • Hanmi- Sanofi launched Robelito, the first ARB-Statin combination drug in Korea
  • NovHanmi launched Naxozol, a NSAIDs-PPI combination drug
  • OctTargeted anti-cancer drug candidate, HM61713, presented recent clinical study during WCLC
  • LAPS-Exendin4 progresses to Multi-National Phase IIb Clinical Studies
  • SepHanmi awarded best biotechnology corporation prize by Korean Ministry of Trade, Industry and Energy in recognition of LAPS-GCSF development
  • RFID history management solution, KEIDAS, achieves 'GS1 EPCglobal' certification
  • AugStudy on Pidogul, anti-thrombotic drug, published in AJCD/Clinical Therapeutics
  • Anti-reflux esophagitis, Esomezol, receives marketing authorization in the US through 505(b)2 procedure
  • JulTargeted anti-cancer drug candidate, HM61713, enters multiracial Phase I study
  • License agreement with Wakamoto for Korean commercialization of MaQaid
  • Export Hanmi IMD (Esomezol, Amosartan, Pidogul), seven countries in SE Asia through DKSH
  • Hepatitis C drug(LAPS-IFNα), Phase II underway in Latin America
  • Chinese Hospital Pharmacists Association visits Hanmi headquarters and R&D center
  • Hanmi melanoma treatment candidate, selected to receive government support
  • Hanmi antibiotic powder injection, achieves the first EU GMP acquisition in the nation
  • Hanmi rheumatoid arthritis drug, Phase I on the European cruise
  • Jun The 7th Hanmi mid-small hospital award, Yutae Jeon, the CEO of Inbong Medical Association
  • Hanmi-Sanofi Korea’s first request for approval, ‘ARB-statin’ a complex new drug
  • Hanmi enters Phase 3 studies, natural new drug for abdominal obesity
  • May Hanmi receives the global ‘best RFID deployment’ award
  • ‘Esomezol’ IMD of Nexium, apply for a first marketing authorization to the U.S. FDA
  • Apr Complex new drug ’Ibastin’ (hypertension + hyperlipidemia), manufacturing technique patent
  • ‘Pidogul’ platelet aggregation, listed on international journals (Clinical Therapeutics)
  • April Hanmi global biopharmaceuticals ‘LAPS-GCSF’, enters Phase II in the U.S.
  • Mar Pharmacy-only energy drink, ‘Premium Recipe’ released
  • Fab 12th annual essay prize award
  • Nasal aerosol rhinitis treatment, ‘Moteson Plus’ released
  • ‘Amosartan’ licensed in the three states of CIS and Uzbek
  • 1st Sound of Light sharing concert
  • Global cancer new drug KX2-391, domestic clinical plunge
  • Jan Online Pharm enters automatic prescription equipment market
  • 'Fenocid' launched for the management of neutral fat

2014

  • Dec Formulation patent for stabilization of targeted anticancer drug granted
  • The 5th Hanmi Proud MD award, Dr. Muyeol Park (Goramdola hospital)
  • Hanmi and Kainos collaborate on new drug development
  • Nov ppreciation plaque from the Korean Red Cross
  • Fixed-dose combination 'Irbestin' collaboration with Sanofi
  • Oct Medicine donation for North Korean flood victims
  • US patent granted for next generation antimycotics formulation
  • Sep Medicine donation to Pyongyang Mankyungdae Univ. Hospital
  • Aug LAPS-Exendin for type 2 diabetes, selected as a government supported project
  • Launched low-dose erectile-dysfunction medication
  • July Launches PalPal Chew Tab. 50mg
  • July Selected as a Pharmaceutical Company of Innovation, by Ministry of Welfare
  • AprIn-licensing deal with SK Biopharmaceuticals for development and commercialization of Diazepam Nasal Spray
  • Beijing Hanmi, accredited as 'R&D Center' by Beijing Government
  • Received the CE mark for Hyalrheuma from UK SGS
  • MarHanmi-GSK, Collaboration agreement for FDC development
  • Launched Koennasal spray (Hyalu acid+Dexpantenol)
  • Hanmi Holdings changed name from Hanmi Holdings to Hanmi Science
  • New anti-obesity, diabetes drug (HM47000), chosen as new drug development program by government
  • FebThe 11th Hanmi literature awards
  • License agreement for anti obesity botanical drug (ALS-L1023)
  • 'Amosartan' published in international academic journals (BMC, AJCD, Clinical Therapeutics)
  • JanLAPS-GCSF, Collaboration with Spectrum (US)
  • Supply agreement for 13 OTC drugs with MEIC(Mongolia)
  • LAPS-GCSF, Collaboration with Spectrum (US)

2014

  • Dec Hanmi Pharmaceutical’s first shipment of ‘AMOSARTAN’ made to MSD
  • Hanmi’s ‘ORASCOVERY’ technology, licensed out to USA
  • Nov Orphan drug designation for LAPS-rhGH applied for
  • Amosartan clinical study is published on BMC Research Note
  • Oct Phase II study of long-acting human growth hormone in European territories
  • JunRetail pharmacists answer that Hanmi's sales reps are the kindest and the most impressive
  • May Hanmi expands its licensing agreement with Merck
  • Apr Hanmi signs a collaboration agreement with Kinex to develop and market a novel anti-cancer drug candidate, KX-01
  • Mar Esomezol receives IR52 Jang Young-Shil Award from KOITA
  • Hanmi's Amosartan ranked the second highest for detailing drugs
  • Feb Hanmi strengthens R&D with a new external collaboration unit
  • Hanmi's Clopidogrel, approved in European countries
  • Jan Hanmi`s Esomezol wins IR52 Jang Young-Shil Award
  • Filed letter with FDA for modified Esomeprazole Capsule
  • R&D reinforcement with a new external collaboration unit (eR&D)

2010

  • DecHanmi transfers entecavir synthetic methods to Hwail
  • Hanmi showcases RFID system in 'RFID/USN KOREA 2010'
  • Beijing Hanmi wins Korea-China Corporate Management Grand Prize
  • NovUK MHRA recommends approval of Pidogul
  • OctHanmi submits IND application for Irbesartan-Atorvastatin combo
  • SepHanmi receives IR52 Jang Young-Shil Award from KOITA
  • AugHanmi initiates the clinical trials of Amosartan in Europe
  • Hanmi ranks 1st in R&D investment among Korean pharmaceutical companies
  • Hanmi submits IMPD in Europe for phase I clinical trials of LAPS-Exendin
  • JulAmosartan, approved as the initial therapy among CCB+ARB hypertension combo drugs
  • Hanmi submits IMPD in Europe for phase I clinical trials of LAPS-Exendin
  • MayPhase I underway for Atorvastatin plus Aspirin fixed dose combination drug
  • JunHanmi wins the best drug research award from KDRA
  • AprLAPSCOVERY Platform Technology obtains US Patents
  • Feb's Amosartan ranked the highest for detailing drugs
  • IND Application for long-acting human growth hormone approved
  • JanKFDA Approves IND application of once monthly Exendin4 analog

2014

  • 2009 Co-promotion agreement with Lundbeck for Ebixa®, a treatment for Alzheimer’s disease
  • Amosartan®, an antihypertensive combination drug of Amodipine and Losartan, launched
  • Co-promotion agreement with GSK in respiration-allergy area
  • 2008 Hanmi-Crystal genomics strategic alliance
  • 2007 KGMP approval on Cephalosporin finished product manufacturing facility in Pyongtaek .
  • First launching of anti-obesity drug ‘Slimmer®’(sibutramine mesilate)
  • 2006 < successful development of mexibufen syrup, using alternative salt
  • Published clinical study for Amodipine®
  • 2004 Patent of Amodipine, a new salt form of Amlodipine, granted
  • Successful development of Fedipine table, a 24hr controlled-release formulation of Nifedipine
  • 2003 Registered as Hanmi Photographic Museum with government
  • Hanmi Pharm. marking its 30-year foundation day anniversary
  • Changes into Hanmi Pharmaceutical Co., Lt
  • Designation of Hanmi’s central research labs as ‘ICE GMP Technology Center’
  • 2002 Establishment of Hanmi Foundation of Art & Culture
  • Completion of Hanmi GMP plant in Beijing
  • 2001 Development of oral antifungal agent ‘Itra tablet’ for 2nd in the world
  • 2000 Successful development of oral anticancer drug Paclitaxel

2014

  • 1998 Making inroads into the European markets through acquisition of COS for the first time in Korea
  • Successful production of G-CSF through transformed black goat ‘Medi’
  • 1997 Hanmi Pharm. broke 100 billion won barrier in sales
  • 1994 Development of cyclosporin A for the 2nd time in the world
  • Ground-breaking ceremony of Beijing Hanmi Pharmaceutical Co., Ltd
  • Technology transfer to Novartis (domestic market)
  • Technology transfer to Novartis (foreign market)
  • 1993 Completion of Hanmi Pharm.’s headquarters at Bangi dong
  • 1989 Technical transfer to Swiss-based Roche; process patent of ceftriaxone
  • Completion of Hanmi Fine Chem.’s Shiwha plant under newly expanded construction
  • 1988 Hanmi Pharm as listed company into Korea’s stock market
  • 1987 Development of third-generation ceftriaxone antibiotic as inject-able form
  • 1986 Accreditation of KGMP standards on all drugs
  • 1985 Synthesis cephalosporin antibiotics
  • 1984 New construction of Paltan GMP plant located at Paltan myeon, Whasung gun, Gyeonggi province
  • 1983 Making of company motto
  • Establishment of Hanmi Fine Chemical Co., an affiliated company of Hanmi Pharm
  • 1978 Making of company’s spirit ‘Creation, Justice, and Deed’
  • 1974 Composition of sales force
  • 1973First launching of trimethoprim sulfamethoxazole powde
  • Change into Hanmi Pharmaceutical Ind. Co., Ltd
  • Establishment of Lim, Sung-ki Pharmaceutical Co., Ltd